Crinetics Pharmaceuticals, Inc. (CRNX) Q2 2021 Earnings Results

Crinetics Pharmaceuticals Misses on EPS, Stock Up 4.27%

Crinetics Pharmaceuticals reported a larger-than-expected loss per share, which typically raises concerns among investors. However, the stock rose by 4.27%, likely driven by positive sentiments around their ongoing clinical trials and management's confidence in their strategy. The lack of revenue data and guidance may leave some investors cautious, but the market reacted favorably to the overall tone of the call.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.70	N/A	-16.67%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management remains focused on advancing their pipeline and emphasized the importance of upcoming milestones. They acknowledged the EPS shortfall but maintained a positive outlook on future developments.

Management highlighted ongoing progress in their clinical trials.

They expressed confidence in their long-term strategy despite the EPS miss.

Crinetics Pharmaceuticals Misses on EPS, Stock Up 4.27%

Key numbers

Management commentary

Crinetics Pharmaceuticals, Inc.

More earnings this week

Crinetics Pharmaceuticals Misses on EPS, Stock Up 4.27%

Key numbers

Management commentary